GLP-1 Chart

Tirzepatide vs Semaglutide

Tirzepatide vs semaglutide: these are two different medicines, each sold under more than one brand.

Prefer

Last updated October 18, 2026. Labels read October 6, 2026.

Learn

More about this page

Tirzepatide is in Mounjaro and Zepbound. Semaglutide is in Ozempic, Wegovy and Rybelsus. This page puts their FDA labels side by side, brand by brand.

The main difference in the labels

The labels describe each medicine by the receptors it acts on. GLP-1 is a gut hormone that helps control blood sugar and food intake, a 2018 review explains. GIP is another hormone the body makes.

  • Tirzepatide: the labels call it a GIP receptor and GLP-1 receptor agonist. It acts on two hormone receptors.
  • Semaglutide: the labels call it a GLP-1 receptor agonist. It acts on one.

Both come as a once weekly shot. Semaglutide also comes as a once daily tablet. The current tirzepatide labels list shots only. For more on how each one acts, see how do GLP-1 drugs work.

Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.

Mounjaro vs Ozempic

These two labels are both about adults with type 2 diabetes. Mounjaro's label also reaches children aged 10 and up, for blood sugar control.

Label factMounjaroOzempic
Medicine (molecule)tirzepatidesemaglutide
TypeGIP and GLP-1
MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
GLP-1
OZEMPIC is a glucagon-like peptide 1 (GLP-1) receptor agonist
Maker on the labelEli Lilly and CompanyNovo Nordisk Pharmaceutical Industries, LP
Taken asInjection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPensInjection: pen or prefilled syringe single-patient-use pens ... single-dose prefilled syringe
How often, per labelOnce weekly Administer MOUNJARO once weekly, any time of day, with or without meals.Once weekly Administer OZEMPIC once weekly, on the same day each week
Approved uses, per label (names only)
  • Blood sugar in type 2 diabetes
  • Lower risk of major cardiovascular events
  • Blood sugar in type 2 diabetes
  • Lower risk of major cardiovascular events
  • Kidney disease with type 2 diabetes
Boxed warningYes WARNING: RISK OF THYROID C-CELL TUMORSYes WARNING: RISK OF THYROID C-CELL TUMORS
Label readMounjaro label, version 40, effective August 27, 2026Ozempic label, version 20, effective June 1, 2026
FDA approval recordNDA215866, first approved May 13, 2022NDA209637, first approved December 5, 2017

Wegovy vs Zepbound

Both labels list excess body weight as a use. Their other uses differ. Wegovy's label also lists cardiovascular risk, and MASH for the shot only. Zepbound's label also lists sleep apnea.

Label factWegovyZepbound
Medicine (molecule)semaglutidetirzepatide
TypeGLP-1
WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist
GIP and GLP-1
ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
Maker on the labelNovo Nordisk Pharmaceutical Industries, LPEli Lilly and Company
Taken asInjection: pen single-patient-use pen (WEGOVY FlexTouch)
Tablet: tablet Take one WEGOVY tablet orally
Injection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens
How often, per labelOnce weekly (injection) Administer WEGOVY injection once weekly, on the same day each week
Once daily (tablet) Take one WEGOVY tablet orally once daily
Once weekly Administer ZEPBOUND once weekly at any time of day, with or without meals.
Approved uses, per label (names only)
  • Lower risk of major cardiovascular events
  • Excess body weight, long term (injection only)
  • Excess body weight, long term (tablets only)
  • MASH liver disease (injection only)
  • Excess body weight, long term
  • Obstructive sleep apnea
Boxed warningYes WARNING: RISK OF THYROID C-CELL TUMORSYes WARNING: RISK OF THYROID C-CELL TUMORS
Label readWegovy label, version 19, effective June 18, 2026Zepbound label, version 40, effective August 28, 2026
FDA approval recordNDA215256, first approved June 4, 2021
NDA218316, first approved December 22, 2025
NDA217806, first approved November 8, 2023

These two tables name each approved use in short. The label's exact words for every use are on the Ozempic vs Wegovy and Mounjaro vs Zepbound pages.

The head to head trial

One trial compared the two medicines directly, in adults with obesity. Here is how its own abstract describes it, with a link to the paper.

TrialDOI 10.1056/NEJMoa2416394
Design, as the abstract states itphase 3b, open-label, controlled trial
Who took part, as statedadult participants with obesity but without type 2 diabetes
Primary end point, as statedThe primary end point was the percent change in weight from baseline to week 72.
Funding, as statedFunded by Eli Lilly

We do not report its results here. This site sticks to label facts, and the trial is not part of either label we read.

More side by side pages

For brands that hold the same medicine, see Ozempic vs Wegovy and Mounjaro vs Zepbound. Any other pair, or three at once, is in the GLP-1 comparison chart.

Questions

What is the difference between tirzepatide and semaglutide?

Tirzepatide and semaglutide are different medicines. Tirzepatide acts on GIP and GLP-1 receptors, its labels say. Semaglutide acts on GLP-1 receptors. Their brands also have different uses and forms.

What is the difference between Mounjaro and Ozempic?

Mounjaro holds tirzepatide and Ozempic holds semaglutide. Both labels are about type 2 diabetes, and both list blood sugar control and cardiovascular risk. Only the Ozempic label adds a kidney use. The Mounjaro label also lists children from age 10 for blood sugar control.

What is the difference between Wegovy and Zepbound?

Wegovy holds semaglutide and Zepbound holds tirzepatide. Both labels list excess body weight. The Wegovy label also lists cardiovascular risk, and MASH for the shot only. The Zepbound label also lists sleep apnea. Wegovy comes as a shot and a tablet, and Zepbound as a shot.

Has tirzepatide been compared with semaglutide in a trial?

Yes. One trial compared tirzepatide with semaglutide directly. It was in adults with obesity but without type 2 diabetes. Its stated primary end point was the percent change in weight from baseline to week 72. The paper is at DOI 10.1056/NEJMoa2416394.

What is the mechanism of action of tirzepatide vs semaglutide?

Tirzepatide binds to and turns on two receptors, GIP and GLP-1, its labels say. Semaglutide binds to and turns on the GLP-1 receptor.

Sources

7 sources with read dates
  1. Mounjaro label on DailyMed, Eli Lilly, version 40 of 2026-08-27, read 2026-10-06
  2. Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
  3. Ozempic label on DailyMed, Novo Nordisk, version 20 of 2026-06-01, read 2026-10-06
  4. Wegovy label on DailyMed, Novo Nordisk, version 19 of 2026-06-18, read 2026-10-06
  5. Rybelsus and Ozempic tablets label on DailyMed, Novo Nordisk, version 14 of 2026-01-30, read 2026-10-06
  6. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
  7. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne LJ and others, N Engl J Med 2025, DOI 10.1056/NEJMoa2416394, abstract read 2026-10-06